Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Feb 2;19(2):134-143.
doi: 10.6004/jnccn.2021.0008.

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

Edward Schaeffer  1 , Sandy Srinivas  2 , Emmanuel S Antonarakis  3 , Andrew J Armstrong  4 , Justin E Bekelman  5 , Heather Cheng  6 , Anthony Victor D'Amico  7 , Brian J Davis  8 , Neil Desai  9 , Tanya Dorff  10 , James A Eastham  11 , Thomas A Farrington  12 , Xin Gao  7 , Eric Mark Horwitz  13 , Joseph E Ippolito  14 , Michael R Kuettel  15 , Joshua M Lang  16 , Rana McKay  17 , Jesse McKenney  18 , George Netto  19 , David F Penson  20 , Julio M Pow-Sang  21 , Robert Reiter  22 , Sylvia Richey  23 , Mack Roach Iii  24 , Stan Rosenfeld  25 , Ahmad Shabsigh  26 , Daniel E Spratt  27 , Benjamin A Teply  28 , Jonathan Tward  29 , Dorothy A Shead  30 , Deborah A Freedman-Cass  30
Affiliations
Practice Guideline

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

Edward Schaeffer et al. J Natl Compr Canc Netw. .

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

PubMed Disclaimer

Publication types